Extended Data Fig. 3: 3-IAA induces a response to FIRINOX in mouse models of PDAC.
From: Microbiota-derived 3-IAA influences chemotherapy efficacy in pancreatic cancer

a, 3-IAA serum concentration of SPF mice gavaged with 500 mg/kg 3-IAA was measured using CLIA at 2, 6 and 24 h after 3-IAA application (n = 3 mice). Unrelated serum concentration of R-microbiota-colonized gnotobiotic mice is shown as a control. b, SPF mice were orthotopically injected with KPC cells and received two treatments of FIRINOX or FIRINOX + 3-IAA (n = 5). Tumour weight at day 20 of the experiment is depicted in the statistic. c, NR-colonized gnotobiotic mice were injected with KPC tumour cells orthotopically. 9 days later, mice were substituted +/− 3-IAA for five days (d9–13) and treated +/− FIRINOX as depicted in the experimental scheme (n = 3 or 4). Tumour weight is shown at day 20 of the experiment. d, SPF mice were orthotopically injected with KPC tumour cells. At day 9 after tumour cell injection, mice were treated with either 500 mg/kg 3-IAA, 3-IPA or 250 mg/kg GCA and 250 mg/kg DCA for five consecutive days (n = 4). FIRINOX treatment was applied at day 11. Tumour weight is shown at day 20 of the experiment. e, As in d, except mice were treated with FIRINOX, FIRINOX + 3-IAA (500 mg/kg) or FIRINOX + hippuric acid (500 mg/kg) (n = 4 or 5). Each symbol represents one mouse. One experiment (e) or one out of two independent experiments is shown (a–d). Error bars indicate SEM, significant p-values are indicated and were determined by Kruskal–Wallis test followed by Dunn’s post-hoc test (a,c,e), or one-way ANOVA followed by Tukey’s (b) or Dunnett’s (d) post-hoc test.